Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis - Takeaways - MDSpire

Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

  • By

  • Yi-Heng Xu

  • Dan Liu

  • Meng-Rui Zhang

  • Yi-Jing Zhang

  • Ming Li

  • Qing-Rui Yang

  • May 20, 2026

  • 0 min

Share

  • 1

    Upadacitinib, a JAK1 inhibitor, shows significant efficacy in improving ACR20 response rates in RA patients compared to control treatments.

  • 2

    Both 15 mg and 30 mg doses of upadacitinib provide comparable clinical benefits, with no significant efficacy difference between them.

  • 3

    The 30 mg dose of upadacitinib is associated with a higher risk of adverse events, including serious infections and elevated liver enzymes.

  • 4

    The 15 mg regimen of upadacitinib may offer a more favorable benefit-risk balance compared to the 30 mg dose.

  • 5

    Further studies are needed to evaluate long-term outcomes and safety of upadacitinib in specific patient populations.

Original Source(s)

Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

  • by Yi-Heng Xu, Dan Liu, Meng-Rui Zhang, Yi-Jing Zhang, Ming Li, Qing-Rui Yang

  • May 20, 2026

Related Content

Ultrasound Models Estimate Whole-Body Muscle Mass

New equations incorporating cross-sectional area improve estimation accuracy.

Obesity Not Associated With Worse Long-Term TAR Outcomes

A long-term cohort study found that obesity was not associated with worse patient-reported outcomes or higher reoperation rates following total ankle replacement in optimized surgical candidates.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.